• 3-Aminobenzamide (PARP-IN-1): Translational Leverage in Dise

  2026-05-24

  Explore how 3-Aminobenzamide (PARP-IN-1), a nanomolar-potency PARP inhibitor available from APExBIO, bridges mechanistic insight and translational strategy. This article decodes the molecular logic of poly (ADP-ribose) polymerase inhibition, integrates breakthrough evidence from virology and nephropathy, and provides actionable protocol guidance for advanced disease modeling. With a unique perspective on cross-domain applications, it equips translational researchers to innovate confidently in cardiovascular, renal, and infectious disease contexts.

• KU-55933: ATM Kinase Inhibitor for DNA Damage Response Resea

  2026-05-23

  KU-55933, a potent and selective ATM kinase inhibitor from APExBIO, empowers researchers to dissect DNA damage response pathways, induce cell cycle arrest, and optimize cancer research and iPSC-based drug screening platforms. Its rigorous selectivity, nanomolar potency, and robust protocol flexibility make it an indispensable tool for translational and personalized medicine workflows.

• Pickering Emulsions Advance mRNA Delivery for Cancer Vaccine

  2026-05-22

  This study develops a multi-level structured Pickering multiple emulsion (mPE) system as an innovative delivery platform for both protein and mRNA cancer vaccines. The approach demonstrates superior dendritic cell targeting, enhanced immune activation, and improved tumor suppression compared to traditional lipid nanoparticle methods, with important implications for the design of next-generation cancer immunotherapies.

• Spermine: Advanced Polyamine Modulation in Nuclear Envelope

  2026-05-22

  Explore Spermine, an endogenous polyamine, as a precision tool for dissecting nuclear envelope dynamics and ion channel regulation. This article uniquely connects Spermine’s mechanistic roles in cell growth and potassium channel modulation with emerging insights from herpesvirus nuclear egress research.

• PD98059 MEK Inhibitor: Optimizing Cell Proliferation and Neu

  2026-05-21

  PD98059, a selective and reversible MEK inhibitor from APExBIO, has become indispensable for dissecting MAPK/ERK pathway function in cell proliferation, apoptosis, and neuroprotection studies. This article outlines practical workflows, troubleshooting tips, and evidence-driven enhancements that maximize the reliability and translational value of experiments using PD98059.

• Cisapride (R 51619): Transforming Cardiac Electrophysiology

  2026-05-21

  Cisapride (R 51619) bridges molecular pharmacology and phenotypic screening, enabling highly sensitive detection of cardiotoxicity and arrhythmia risk in human stem cell-derived cardiomyocytes. APExBIO delivers unmatched solubility, QC, and workflow reproducibility—making Cisapride the gold standard for cardiac electrophysiology research and hERG channel inhibition assays.

• Ruxolitinib Targets DRP1-Mediated Mitochondrial Fission in A

  2026-05-20

  The referenced study reveals that ruxolitinib, by inhibiting DRP1-mediated mitochondrial fission through suppression of the JAK1/2-STAT3 pathway, induces both apoptosis and pyroptosis in anaplastic thyroid carcinoma (ATC) cells. These findings offer mechanistic insight into mitochondrial dynamics as a therapeutic target in aggressive thyroid cancers and support new avenues for apoptosis detection and mitochondrial dysfunction research.

• Pioglitazone: PPARγ Agonist Workflows for Metabolic & Inflam

  2026-05-20

  Pioglitazone stands out as a selective PPARγ agonist, enabling researchers to dissect metabolic and inflammatory pathways with precision. This article translates recent mechanistic advances and experimental benchmarks into clear, actionable protocols and troubleshooting tips—empowering reproducible discovery in diabetes, neurodegeneration, and immune modulation.

• Deferasirox Fe3+ Chelate: Workflows for Iron Overload Resear

  2026-05-19

  Deferasirox Fe3+ chelate empowers researchers with a DMSO-soluble, high-purity tool for dissecting iron overload mechanisms in beta-thalassemia and chronic anemia models. This article demystifies protocol optimization, comparative advantages, and troubleshooting strategies for maximizing the impact of Exjade-based iron chelation studies.

• Evaluating Phebestin: A Novel Aminopeptidase Inhibitor Again

  2026-05-19

  The reference study introduces phebestin, a bestatin-related aminopeptidase inhibitor, as a potent agent against both chloroquine-sensitive and -resistant Plasmodium falciparum at nanomolar concentrations. Its efficacy in vitro and in vivo, alongside low cytotoxicity, highlights phebestin’s potential as a new chemotherapeutic target for malaria, offering insight into peptidase inhibition as a promising strategy amid rising drug resistance.

• CRISPR Editing of LGMN Suppresses Breast Cancer Metastasis

  2026-05-18

  This study demonstrates that co-delivery of Cas9 mRNA and guide RNAs targeting the LGMN gene impairs metastatic potential in breast cancer cells. The findings highlight a robust T7 RNA polymerase transcription workflow for generating functional RNA components and suggest new avenues for RNA-based cancer therapeutics.

• Palomid 529: Precision PI3K/Akt/mTOR Inhibition for Cancer R

  2026-05-18

  Palomid 529 (P529) offers researchers a robust tool for dissecting and targeting the PI3K/Akt/mTOR signaling axis in both cancer and neural models. Its dual mTORC1/mTORC2 inhibition, validated antitumor potency, and compatibility with radiotherapy and angiogenesis assays distinguish it for advanced experimental workflows.

• Deferasirox Fe3+ Chelate: Precision in Iron Overload Researc

  2026-05-17

  Deferasirox Fe3+ chelate (Exjade) delivers high reproducibility and solubility for modeling iron overload in beta-thalassemia and chronic anemia research. Its robust chelation efficiency and workflow compatibility empower advanced studies in iron metabolism and lysosomal cell death.

• Oteseconazole (VT-1161): Precision Antifungal Profiling for

  2026-05-16

  Explore the advanced antifungal mechanism and selectivity of Oteseconazole (VT-1161) against Candida species, including fluconazole-resistant strains. This article delivers deep insights into assay design, resistance management, and how Oteseconazole reshapes antifungal research workflows.

• Revisiting Sumatriptan Metabolism: CYP and MAO Pathways Unve

  2026-05-15

  This study challenges the conventional view of sumatriptan metabolism, demonstrating that cytochrome P450 enzymes (CYP1A2, CYP2C19, CYP2D6) contribute to N-demethylation alongside MAO A-mediated deamination. These findings refine our understanding of metabolic pathways relevant to basic amine-containing drugs and inform the design of neurodegenerative disease models.

479 records 19/32 page Previous Next First page 上5页 1617181920 下5页 Last page